Abzena plc
https://abzena.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abzena plc
Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy
Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.
Deals Shaping the Medical Industry, August 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
Medherant Builds Senior Exec Team
UK transdermal drug delivery firm Medherant is expanding its top management team with a number of new senior executive appointments, including a new chief operating officer and chief financial officer.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- ADC Cascade
- Antitope Ltd.
- Astro Bidco Limited
- Biologics Cascade
- PacificGMP
- PolyTherics, Ltd.
- TCRS
- WCAS XII-Astro, L.P.